Sex-related differences in the pharmacological treatment of heart failure

Impacto

Downloads

Downloads per month over past year

Tamargo Menéndez, Juán and Caballero Collado, Ricardo and Delpon Mosquera, María Eva (2022) Sex-related differences in the pharmacological treatment of heart failure. Pharmacology & Therapeutics, 229 . p. 107891. ISSN 0163-7258

[thumbnail of 1-s2.0-S0163725821000930-main.pdf]
Preview
PDF
Creative Commons Attribution Non-commercial No Derivatives.

925kB

Official URL: https://doi.org/10.1016/j.pharmthera.2021.107891




Abstract

Heart failure (HF) represents a leading cause of morbidity and mortality. However, HF trials highlighted many differences between men and women with HF. Thus, women represent approximately a quarter of people with HF with reduced ejection fraction (HFrEF), while they account for over half of those with HF with preserved EF (HFpEF). There are also sex-related differences (SRDs) in the pharmacokinetics, pharmacodynamics and safety profile of some guideline-recommended drugs for the treatment of HF. As compared with men, women with HFrEF are less often treated with guideline-recommended HF drugs, experience more frequent and severe adverse reactions when these drugs are prescribed at the same doses in both sexes, and recent evidence suggests that women might need lower doses than men, bringing into question which are the optimal doses of HF drugs in women and men separately. However, information on SRDs in drug efficacy and safety in patients with HFrEF is very limited due to the underrepresentation of women and the lack of sex-specific evaluations of drug efficacy and safety in HF clinical trials. As a consequence, current clinical guidelines do not provide sex-specific recommendations, even when significant differences exist, at least, in drug safety. The aim of this article is to review the SRDs in the pharmacokinetics, efficacy and safety of guideline-recommended HF drugs and to identify emerging areas of research to improve our understanding of the SRDs, because a better understanding of these differences is the first step to achieve a personalized treatment of HF in women and men.


Item Type:Article
Additional Information:

CRUE-CSIC (Acuerdos Transformativos 2021)

Uncontrolled Keywords:Sex-related differences, Women, Heart failure, Pharmacokinetics, Pharmacodynamics, Adverse drug reactions
Subjects:Medical sciences > Medicine > Cardiology
Medical sciences > Medicine > Pharmacology
ID Code:70554
Deposited On:21 Feb 2022 14:23
Last Modified:18 Oct 2022 08:55

Origin of downloads

Repository Staff Only: item control page